Navigation Links
Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
Date:9/17/2007

Next-Generation Once-Daily CCR5 Antagonist Designed to Block HIV Infection

of Immune System Cells

KENILWORTH, N.J., Sept. 17 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced that it has initiated two large Phase III clinical studies with vicriviroc, its investigational CCR5 antagonist, administered once-daily as a single 30 mg tablet in combination with an optimized background therapy that must include a protease inhibitor boosted by ritonavir in adult treatment-experienced HIV patients with R5-type virus only. Vicriviroc is a next-generation extracellular inhibitor of HIV infection designed to block entry of infectious virions into uninfected CD4 cells via antagonism of the CCR5 co-receptor.

The vicriviroc Phase III clinical program builds upon previous studies in HIV treatment-experienced patients, including a Phase II study (ACTG 5211) in which vicriviroc demonstrated potent and sustained viral suppression through 48 weeks of therapy.(1)

The two Phase III studies, known as VICTOR-E3 and VICTOR-E4 (Vicriviroc in Combination Treatment with an Optimized Antiretroviral Therapy Regimen in HIV- Infected Treatment-Experienced Subjects), will evaluate the virologic benefit of adding vicriviroc 30 mg once daily to an optimized background therapy compared to a control group receiving new optimized background therapy alone. The studies will also evaluate the safety and tolerability of vicriviroc compared to placebo. The optimized background therapy must include at least two drugs that are active, based on susceptibility testing. Patients coinfected with hepatitis C may be included in the studies and there are no exclusions of commonly prescribed drug
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Schering-Plough Announces Hepatitis C Data Presentations at Digestive Disease Week (DDW) 2007 Annual Meeting
2. Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C
3. Schering-Plough Announces Presentation of Phase II Trial Results for Novel Oral Thrombin Receptor Antagonist at the 2007 Annual Meeting of The American College of Cardiology/i2 Summit
4. Malvern initiates European user group meetings for chemical imaging
5. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
6. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... LONDON , Aug. 27, 2014 /PRNewswire/ ... research report: Collaborative R&D Terms ... https://www.reportbuyer.com/product/2276220/Collaborative-RD-Terms--Agreements-in-Pharma-Biotech-and-Diagnostics.html The ... Biotech and Diagnostics report provides comprehensive understanding ... deals and agreements entered into by the ...
(Date:8/27/2014)... , Aug. 27, 2014 /PRNewswire-iReach/ -- In ... to bridge the gap between the electronic medical ... embedded links, readers can experience, first-hand, how seamless ... record. Photo - http://photos.prnewswire.com/prnh/20140827/140443 ... central access to imaging from within the patient ...
(Date:8/27/2014)... 27, 2014 About 8 million Americans have ... buildup of fatty plaque in the arteries, according to ... population and in incidences of diabetes and obesity, the ... Lower Extremity Arterial RevascularizatioN (LEARN) meeting, Oct. 9–11 ... and interested residents and fellows will be able to ...
Breaking Medicine Technology:Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 2Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 3Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 4Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 5Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 6Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 7Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 8Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 9DICOM Grid Launches Interactive Guide to Demonstrate Image-Enabling the EMR 2LEARN to Treat Peripheral Arterial Disease Patients 2LEARN to Treat Peripheral Arterial Disease Patients 3
... Essence Orthopaedics, Inc., a medical device company focused on ... has introduced their novel, surgeon-designed PONTiS™ Knotless Endotendonous Repair ... Society for Surgery of the Hand (ASSH). ... upper and lower extremity markets, Core Essence Orthopaedics developed ...
... Optimer Pharmaceuticals (NASDAQ: OPTR ) today ... DIFICID™ (fidaxomicin) tablets will be presented at the 2011 ... place September 17-20 in Chicago. DIFICID was approved by ... of 2011 for the treatment of Clostridium difficile ...
Cached Medicine Technology:Core Essence Orthopaedics Unveiled New Flexor Tendon Repair System at ASSH 2011 2Optimer Pharmaceuticals' DIFICID Featured in 11 Presentations at 51st ICAAC 2Optimer Pharmaceuticals' DIFICID Featured in 11 Presentations at 51st ICAAC 3Optimer Pharmaceuticals' DIFICID Featured in 11 Presentations at 51st ICAAC 4Optimer Pharmaceuticals' DIFICID Featured in 11 Presentations at 51st ICAAC 5
(Date:8/27/2014)... Recently, Skmen.com, a renowned garment manufacturer and retailer, has ... . The company has rich experience in making fashionable ... stock and ready to ship: celebrity bodycon dresses, mini ... and so forth. All of them are available in ... proud to announce the new collection of celebrity bodycon ...
(Date:8/27/2014)... August 27, 2014 Taking its popular obstacle ... Steele Creek YMCA will host its largest crowd at ... Saturday, September 13 at YMCA Camp Thunderbird . ... divisions: adult, youth and teams. Within each division, runners ... their physical limit - for a worthy cause. All ...
(Date:8/27/2014)... 2014 Today, Zane Benefits, the #1 ... tips for administering a premium reimbursement plan. , ... effect, compliance is top of mind for employers, health ... health insurance and premium reimbursement, there are important compliance ... 35 minute webinar, Zane Benefits President, Rick Lindquist, will ...
(Date:8/27/2014)... Skirt Sports , the innovative women’s running apparel ... Kathrine Switzer, most noted for her brave running of the ... of women’s running clothes that unites the history of women’s ... Movement. , “It is such an honor to ... “Kathrine is the original Skirt – she stood strong, pushing ...
(Date:8/27/2014)... the use of hormone therapy has spawned a prevalent ... silence with hot flashes, according to a study by ... , In the study published in the Aug. 27 ... team found that moderate to severe hot flashes ... in most women. Women with VMS experience more than ...
Breaking Medicine News(10 mins):Health News:Skmen.com Unveils Its New Celebrity Bodycon Dresses for Its Loyal Customers 2Health News:C2 Survival Racers Go to Extremes to Provide Kids with YMCA Programs 2Health News:Zane Benefits Announces Upcoming Webinar on Compliance 2Health News:Skirt Sports Launches Clothing Line with Legendary Runner Kathrine Switzer 2Health News:The high cost of hot flashes: Millions in lost wages preventable 2
... Upgrades new facility from film to IDC 1600 ... - IDC (Imaging Dynamics Company,Ltd.) (TSX: IDL), the ... radiography (DR), today announced that HealthPartners Medical Group,of ... X-Series DR system.,HealthPartners is a multi-specialty physician group ...
... a range of $395 Million to $405 Million; ... ... up 57.4% over first quarter 2007 - Gross profit of $23.9 million, ... up 135.4% over first quarter 2007, WARSAW, Ind., June 24 Symmetry Medical ...
... Exposure Increased 38% From 2001 - 2007, ... advertising practices by alcohol companies from 2001-2007,finds an ... relatively,few industry- sponsored "responsibility" ads. The new study, ... Youth (CAMY) at Georgetown,University, evaluated advertising trends and ...
... Research,Inc. (ADR), one of the world,s leading scientific institutes ... to announce that it,has achieved legal status as a ... fully-operational for a while now," says,Dr. Catlin, a founder ... all official and we,re thrilled, because others can now ...
... China, TUSTIN, Calif., June 24 AMDL, ... specialty pharmaceuticals,announced today its subsidiary Jade Pharmaceutical, Inc. ... two new formulations of its,popular Goodnak(R) anti-aging skin ... injectable formulation, JPI anticipates offering Goodnak in,capsules and ...
... ultrasound exam of the heel may be able to predict ... to osteoporosis, according to a new multicenter study being published ... Along with certain risk factors, including age or recent fall, ... select women who need further bone density testing, such as ...
Cached Medicine News:Health News:HealthPartners Medical Group in Michigan City purchases IDC digital radiography system 2Health News:HealthPartners Medical Group in Michigan City purchases IDC digital radiography system 3Health News:Symmetry Medical Reports Record First Quarter 2008 Revenue of $101.9 Million 2Health News:Symmetry Medical Reports Record First Quarter 2008 Revenue of $101.9 Million 3Health News:Symmetry Medical Reports Record First Quarter 2008 Revenue of $101.9 Million 4Health News:Symmetry Medical Reports Record First Quarter 2008 Revenue of $101.9 Million 5Health News:Symmetry Medical Reports Record First Quarter 2008 Revenue of $101.9 Million 6Health News:Symmetry Medical Reports Record First Quarter 2008 Revenue of $101.9 Million 7Health News:Symmetry Medical Reports Record First Quarter 2008 Revenue of $101.9 Million 8Health News:Alcohol Advertisements Seen by Youth on TV on the Rise, According to a New Report by the Center on Alcohol Marketing and Youth 2Health News:Alcohol Advertisements Seen by Youth on TV on the Rise, According to a New Report by the Center on Alcohol Marketing and Youth 3Health News:Leading Performance-Enhancing Drug Research Institute Anti-Doping Research (ADR) Establishes Nonprofit Status 2Health News:AMDL's Goodnak(R) Anti-Aging Skin Care Line Soon Available in Capsule & Lotion Form 2Health News:Simple ultrasound exam may predict osteoporosis risk 2
... Pulse Oximeter monitors SpO2, pulse ... is designed to provide fast, ... The device rejects spontaneous motion ... operator of excess artifacts and ...
... Radical can operate in two additional ... be removed, creating a fully featured handheld ... also be used to upgrade existing equipment ... additinal hardware or software upgrades to improve ...
Halogen-free immersion oil based on ester oil....
Immersion Oil, 150 cs...
Medicine Products: